KPV Research: What Published Studies Have Investigated

What is KPV?

What is KPV? It is a tripeptide of three amino acids — lysine, proline and valine (Lys-Pro-Val) — corresponding to the carboxy-terminal residues 11–13 of α-melanocyte-stimulating hormone (α-MSH). It is one of the most-studied α-MSH-derived message fragments in the anti-inflammatory research literature. In preclinical work, KPV is reported to retain the anti-inflammatory activity attributed to the parent hormone’s C-terminus while lacking α-MSH’s pigmentary (melanocortin) signalling. That is a neutral molecular definition; the sections below describe what researchers examined in cell and animal models, not effects in people.

Molecule properties

KPV is a three-residue peptide (Lys-Pro-Val) with a very low molecular weight relative to the full peptides catalogued alongside it, a direct consequence of its α-MSH-fragment origin. In research catalogues it is supplied as a lyophilized powder and handled as a research peptide. A recurring theme in the literature is the endogenous-fragment versus synthetic (research-grade) distinction: the same short sequence occurs as a natural cleavage product of α-MSH and is also prepared synthetically for study. Because of its small size, KPV features prominently in delivery- and formulation-focused work, where its uptake and stability are the object of investigation. These are molecule facts only — no handling or reconstitution guidance is given here.

Mechanisms researchers have examined

The KPV peptide mechanism literature is unusually clean for a short peptide, converging on a transporter-mediated, receptor-independent story. Each direction below is framed as what researchers examined in preclinical models:

• PepT1-mediated cellular uptake — Dalmasso et al. (2008, Gastroenterology, PMID 18061177) reported that KPV is taken up into intestinal epithelial and immune cells via the di/tripeptide transporter hPepT1 — a transporter noted as upregulated in inflamed tissue — and that the anti-inflammatory action observed in those cell and rodent models did not require melanocortin receptors.
• NF-kB and MAP-kinase signalling — the same and related work reported that nanomolar KPV was associated in vitro with reduced activation of the NF-kB and MAP-kinase inflammatory signalling cascades and lower pro-inflammatory cytokine output in cell models. These are neutral observations in cultured cells, not effects in a reader.
• C-terminal α-MSH structure–activity — Getting et al. (2003, J Pharmacol Exp Ther, PMID 12750433) dissected the anti-inflammatory contribution of the core versus the C-terminal (KPV) regions of α-MSH across preclinical inflammation assays.
• Formulation / targeted delivery — Xiao et al. (2017, Molecular Therapy, PMID 28143741) examined hyaluronic-acid-functionalized nanoparticles as an oral delivery vehicle for KPV in a mouse colitis model, framed as a delivery-science question rather than a use recommendation.

The section closes as the literature does: KPV has been characterized primarily in cell and rodent models, and a receptor-independent, transporter-mediated anti-inflammatory mechanism is the recurring research theme. Each bullet names a pathway examined in a model system, not an effect in a person.

Research models in the literature

The KPV literature is built almost entirely on preclinical systems. In vitro, studies used cultured intestinal epithelial and immune cell lines to probe uptake and signalling. In vivo, the recurring tools are rodent chemically-induced colitis models — dextran sodium sulfate (DSS) and trinitrobenzene sulfonic acid (TNBS) — used by Dalmasso et al. (2008). Kannengiesser et al. (2008, Inflammatory Bowel Diseases, PMID 18092346) added a CD45RB-transfer colitis model and melanocortin-1-receptor-deficient (MC1Re/e) mice specifically to probe whether the effects depended on melanocortin-receptor signalling. The delivery-formulation work of Xiao et al. (2017) used a mouse ulcerative-colitis model to test its nanoparticle vehicle.

It is worth stating plainly, and more than once: the body of evidence for KPV is preclinical — cell and rodent — and there is essentially no interventional human clinical trial data. The literature is also relatively small and concentrated in the intestinal-inflammation area, with additional exploratory work in skin/keratinocyte and wound-model settings that remains preliminary. Read accurately, these are studies that investigated KPV in defined model systems; they describe what was observed in those models and do not establish that a reader would experience any effect. That framing is deliberate: an in-vitro or animal observation cannot be translated into a human outcome, and the citations here point back to the named studies so each mechanism is reported as what was investigated rather than what was concluded about people.

KPV among the α-MSH-derived peptides

In the research literature KPV is positioned within the broader melanocortin / α-MSH message-fragment family, and the useful contrast is a research-focus one rather than a ranking. What distinguishes KPV as a research target is that it is a minimal C-terminal fragment studied for anti-inflammatory activity that appears decoupled from the melanocortin-receptor pigmentary signalling of its parent hormone — a point drawn out in the Brzoska/Luger review (2010, PMID 21222263). That decoupling is precisely why KPV and a pigmentary melanocortin analog such as Melanotan-2 are studied as separate mechanistic questions rather than interchangeable molecules. For a different anti-inflammatory research peptide catalogued alongside it, see GHK-Cu research, and for a tissue-repair research peptide often discussed in the same catalogue, TB-500 research. This page hands off to those pages rather than combining or comparing them as protocols.

Research-grade sourcing and verification

For laboratory research use only, KPV is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation — lot-level checks that matter especially for a short peptide, where identity and purity confirmation are the whole assurance. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This is sourcing and quality-assurance framing only, not an outcome claim.

Frequently asked questions

Literature cited

1. Getting SJ, Schiöth HB, Perretti M. “Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.” Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631–637. PMID 12750433.
2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. “PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation.” Gastroenterology. 2008;134(1):166–178. PMID 18061177; PMCID PMC2431115.
3. Kannengiesser K, Maaser C, Heidemann J, et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases. 2008;14(3):324–331. PMID 18092346.
4. Xiao B, Xu Z, Viennois E, et al. “Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.” Molecular Therapy. 2017;25(7):1628–1640. PMID 28143741.
5. Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. “Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.” Advances in Experimental Medicine and Biology. 2010;681:107–116. PMID 21222263.